Topiramate for Treatment of Patients With Borderline Personality Disorder and Alcohol Dependence

• Status: Withdrawn
• Trial end date: 2009-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of the present study is to evaluate the efficacy of topiramate (250mg/day) versus placebo in decreasing aggression and reducing alcohol consumption in patients with borderline personality disorder (BPD) and alcohol dependence (AD).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Elizabeth Ralevski
• Treatments: Ethanol; Topiramate

Criteria

Inclusion Criteria:

• Diagnosis of AD

• Diagnosis of BPD

Exclusion Criteria:

• Serious or unstable medical condition

• Opiate dependence

• Major Axis I disorder (bipolar disorder, schizophrenia)

• Taking mood stabilizers and antipsychotic medications

• LFT abnormalities that do not exceed 3 times normal values